Prime Medicine Inc (PRME)
Prime Medicine, Inc. is a biotechnology company focused on developing genetic medicines through gene editing technology. The company’s pipeline includes PM359 for chronic granulomatous disease, which is in a Phase 1/2 clinical trial, as well as PM577 for Wilson disease in preclinical development and PM647 for a genetic disorder linked to SERPINA1 mutations. It also advances in vivo programs directed at liver diseases and cystic fibrosis. Prime Medicine’s platform centers on Prime Editing, a programmable approach designed to write new DNA sequence information at targeted genomic sites, and the company has collaborations and license agreements with Bristol Myers Squibb, the Cystic Fibrosis Foundation, the Broad Institute, and Beam. Incorporated in 2019, Prime Medicine is headquartered in Cambridge, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PRME
|
$3.11
|
-0.1% Downside
|
Fair
|
$7.12
|
128.8% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-2.8x
|
7.4x
|
140.1x
|
550.9 M
|
544.3 M
|
17.2%
|
63.7%
|
-4.8
|
—
|
80.0%
|
